Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to Hold at StockNews.com

StockNews.com cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a hold rating in a report issued on Sunday morning.

ALNY has been the subject of a number of other reports. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an equal weight rating for the company in a research report on Tuesday, February 13th. Cantor Fitzgerald restated a neutral rating and set a $165.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Wells Fargo & Company decreased their target price on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an equal weight rating for the company in a research note on Friday, February 16th. William Blair restated an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Finally, Citigroup decreased their target price on Alnylam Pharmaceuticals from $237.00 to $227.00 and set a buy rating for the company in a research note on Friday, February 16th. Nine investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $216.12.

Alnylam Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ:ALNY opened at $146.07 on Friday. The business has a 50-day moving average price of $151.09 and a 200 day moving average price of $166.50. The company has a market capitalization of $18.40 billion, a price-to-earnings ratio of -41.03 and a beta of 0.39. Alnylam Pharmaceuticals has a 12-month low of $143.50 and a 12-month high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. The business’s revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.68) earnings per share. As a group, equities research analysts predict that Alnylam Pharmaceuticals will post -4.54 earnings per share for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Harbor Capital Advisors Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 1.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 51 shares during the last quarter. EP Wealth Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 6.4% in the 3rd quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 71 shares during the last quarter. Commerce Bank lifted its holdings in shares of Alnylam Pharmaceuticals by 1.7% in the 4th quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock worth $896,000 after purchasing an additional 77 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its stake in Alnylam Pharmaceuticals by 7.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 89 shares in the last quarter. Finally, Oppenheimer & Co. Inc. raised its stake in Alnylam Pharmaceuticals by 2.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock valued at $800,000 after acquiring an additional 93 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.